Arvind Kumar retweetledi
Thrilled to announce our latest findings: SGLT2 inhibitor therapy is associated with significantly improved patient QOL & exercise capacity!
So grateful to collaborate with many amazing mentors--with a special thank you to @dranulala and @SantosGallegoMD!
Anu Lala (Anuradha Lala-Trindade)@dranulala
Exciting to see our meta-analysis of 🚶🏽♀️🚶♂️ & QOL benefits of SGLT2i across sex, DM, EF in > 22000 pts @JAMANetworkOpen! +13 m can mean diff btwn being confined to one’s 🏡 or being able to 🚶🏽♀️ across the st. 🙌🏽 context 📖 before #ACC24- where effects of empagliflozin in setting of MI & aldose reductase inhibitor on peak VO2 in DM Stage B HF will be presented! jamanetwork.com/journals/jaman…
English
